Companies › ParVation Therapeutics
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DB-1310 | – | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| SNV1521 PARP inhibitor | – | Phase 1 | Advanced Solid Tumor; Pancreatic Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06220864 | SNV1521 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT06220864 | DB-1310 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT07756281 | SNV1521 | Phase 1 | Pancreatic Cancer | Oncology | Jun 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.